How do I buy Precigen, Inc. Common Stock (PGEN) stock?

Buying Precigen, Inc. Common Stock (PGEN) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "PGEN", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy PGEN by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for PGEN on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Precigen, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Precigen, Inc. Common Stock (PGEN) pay dividends?

At the moment, Precigen, Inc. Common Stock (PGEN) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track PGEN's performance via the price chart in the Gotrade app.

Is buying PGEN on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy PGEN?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if PGEN is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Precigen, Inc. Common Stock (PGEN) Stock Price: Nov 11 Close $4.72

Latest news

Stocktwits

Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock

PGENNovember 5, 2026

Stocktwits

Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock

PGEN

Zacks Investment Research

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

PositivePGENNovember 2, 2026

Zacks Investment ResearchPositive

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

PGEN

Stocktwits

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

PGENOctober 30, 2026

Stocktwits

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

PGEN

Zacks Investment Research

News tone: automated (AI) classification of the article's content, not a price prediction.

About Precigen, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees160

CEODr. Helen Sabzevari MPH, Ph.D.

IPO DateSep 25, 2018

HeadquartersGermantown, MD

Key Executives

Name	Title	Year Born
Dr. Helen Sabzevari MPH, Ph.D.	President, CEO & Director	1962
Mr. Randal J. Kirk J.D.	Executive Chairman	1953
Mr. Harry Thomasian Jr.	Chief Financial Officer	1962
Mr. Rutul R. Shah	Chief Operating Officer	1981
Mr. Donald P. Lehr J.D., Ph.D.	Chief Legal Officer & Corporate Secretary	1975
Mr. Phil Tennant	Chief Commercial Officer	1970
Mr. Steven M. Harasym	VP & Head of Investor Relations	—
Dr. Douglas E. Brough Ph.D.	Senior VP & Head of Research	1955
Dr. Bryan T. Butman Ph.D.	Senior VP & Head of CMC	1953

Fundamentals

Valuation

Price-to-sales ratio10.33

Price-to-book value19.34

Profitability

Return on Equity58.00%

Return on Assets14.00%

Return on Sales23.00%

Gross margin (latest quarter)91.22%

EBITDA$40.87M

Trading

Average volume7,386,368

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 35.70
MACD 12/26/9: -0.70
EMA 9 of MACD: -0.57
MACD histogram: -0.13
SMA 50: $6.84; Price below SMA 50
EMA 50: $6.32; Price below EMA 50
SMA 200: $5.28; Price below SMA 200
EMA 200: $5.45; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

2 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $12.00
Average: $12.00
High: $12.00

B. Riley Securities

Yuan Zhi

Buy

Target price

$12.00

Citizens

Jason N. Butler

Buy

Target price

$12.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-0.5	-3.6
2022	-35.2	-13.5	-2.3	-41.4	-4.3	+9.8	+11.3	+43.5	-7.4	-19.8	+7.7	-16.5
2023	+9.5	-25.4	-7.8	+8.0	+0.8	-10.9	+23.0	+35.7	-21.5	-12.4	+4.7	+12.6
2024	-2.1	+10.0	-14.2	-7.7	+0.0	+1.3	-1.9	-23.1	-10.4	-16.8	+13.4	+23.1
2025	+25.0	+33.1	-10.8	+8.3	-14.8	+6.8	+17.9	+170.1	-30.9	+24.0	-7.9	+15.8
2026	+4.9	-21.5	+6.9	+5.9	+6.4	+38.3	+19.4	+4.8	+24.8	-15.5	-8.2

Compare stocks

PGEN

Buy PGEN

Market cap

$1.69B

-

Price / Earnings ratio

66.40

-

Price / Sales ratio

10.33

-

Dividend yield

0.00%

-

Average volume

7,386,368

-

Earnings per share

$0.13

-

Precigen, Inc. Common Stock (PGEN) Stock

Key stats

Compare with PGEN

Recent news

Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock

Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock

Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?

MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

About Precigen, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade